Disease Long-Term Care Facilities Trials 
The Pharma Data
DECEMBER 17, 2020
COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.
PPD
MAY 11, 2023
To effectively implement vaccine clinical trials for special populations, it is critical for vaccine developers to partner with a contract research organization (CRO) that has demonstrated experience recruiting and retaining pediatric and elderly study participants — and managing the nuances these patients and their caregivers require.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 4, 2020
As for Fauci, Biden made it clear that the nation’s top infectious diseases expert would be a central player in the U.S. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported. Just 100 days to mask — not forever, just 100 days.
The Pharma Data
DECEMBER 3, 2020
Centers for Disease Control and Prevention warned Wednesday that the coming winter months might be the darkest period yet in the coronavirus pandemic. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported. THURSDAY, Dec. A global scourge.
The Pharma Data
DECEMBER 19, 2020
Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. .–( BUSINESS WIRE )– Moderna, Inc., AUTHORIZED USE.
The Pharma Data
APRIL 14, 2021
Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg alone or placebo were nausea (3% vs 4%), diarrhea (1% vs 5%), dizziness (3% vs 2%), headache (3% vs 2%), pruritus (2% vs 1%) and vomiting (1% vs 3%). Bamlanivimab alone. It was identified from a blood sample taken from one of the first U.S.
The Pharma Data
DECEMBER 2, 2020
The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. The global race to develop a vaccine has been stunningly fast.
Expert insights. Personalized for you.
52 
Let's personalize your content